BioStock: Spago Nanomedical enters Nasdaq First North Growth Market

Earlier this year, Lund-based Spago Nanomedical completed an oversubscribed rights issue to keep the pace in their cancer treatment project Tumorad. Now, the company has also made a change of listing to Nasdaq First North Growth Market, a change that supports the company’s development and ambitions. BioStock reached out to CEO Mats Hansen for a comment.

Read the interview with Spago Nanomedical's CEO Mats Hansen at biostock.se:

https://www.biostock.se/en/spago-nanomedical-enters-nasdaq-first-north-growth-market/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/